PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the Company in its Angiomax® (bivalirudin) patent litigation with Hospira, Inc. In its ruling today, the Federal Circuit held that U.S. Patent Nos. 7,582,727 (the ‘727 patent) and 7,598,343 (the ‘343 patent) are invalid. On March 31, 2014, the U.S. District Court of Delaware found that all of the asserted claims of the ‘727 patent and the ‘34